

## CLAIMS

### WHAT IS CLAIMED IS:

1. A nucleic acid molecule that binds or is complementary to a polynucleotide encoding exon 44 of the DMD gene, wherein the polynucleotide encoding exon 44 comprises or consists of the nucleotide sequence set out in SEQ ID NO: 1 or 2 or encodes the amino acid sequence set out in SEQ ID NO: 3.
2. The nucleic acid molecule of claim 1 that binds or is complementary to at least one of the nucleotide sequences set out in SEQ ID NO: 4, 5, 6, 7, 32, 33, 34, or 35.
3. The nucleic acid molecule of claim 1 or 2 comprising or consisting of a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence set out in SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 32, 33, 34, or 35.
4. The nucleic acid molecule of any one of claims 1-3 comprising or consisting of a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence set out in SEQ ID NO: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28.
5. The nucleic acid molecule of claim 1, 2, or 3 comprising or consisting of the nucleotide sequence set out in SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 32, 33, 34, or 35.
6. The nucleic acid molecule of any one of claims 1-4 comprising or consisting of the nucleotide sequence set out in SEQ ID NO: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28.
7. A recombinant adeno-associated virus (rAAV) comprising a genome comprising at least one of the nucleic acid molecules of any one of claims 1-6.
8. The rAAV of claim 7 wherein the genome is a self-complementary genome or a single-stranded genome.
9. The rAAV of claim 7 or 8 wherein the rAAV is rAAV-1, rAAV-2, rAAV-3, rAAV-4, rAAV-5, rAAV-6, rAAV-7, rAAV-8, rAAV-9, rAAV-10, rAAV-11, rAAV-12, rAAV-13, rAAV-rh74, or rAAV-anc80.
10. The rAAV of claim of any one of claims 7-9 wherein the genome of the rAAV lacks AAV rep and cap DNA.

11. The rAAV of claim 10 further comprising an AAV-1 capsid, an AAV-2 capsid, an AAV-3 capsid, an AAV-4 capsid, an AAV-5 capsid, an AAV-6 capsid, an AAV-7 capsid, an AAV-8 capsid, an AAV-9 capsid, an AAV-10 capsid, an AAV-11 capsid, an AAV-12 capsid, an AAV-13 capsid, an AAV-rh74 capsid, or an AAV-anc80 capsid.

12. A method for inducing skipping of exon 44 of the DMD gene in a cell, the method comprising providing the cell with the nucleic acid molecule of any one of claims 1-6.

13. A method for inducing skipping of exon 44 of the DMD gene in a cell, the method comprising providing the cell with the rAAV of any one of claims 7-11.

14. A method for treating, ameliorating, and/or preventing a muscular dystrophy in a subject with a mutation amenable to skipping exon 44 of the DMD gene (DMD exon 44) comprising administering to the subject at least one of the nucleic acid molecules of any one of claims 1-6.

15. A method for treating, ameliorating, and/or preventing a muscular dystrophy in a subject with a mutation amenable to skipping exon 44 of the DMD gene (DMD exon 44) comprising administering to the subject at least one of the rAAV of any one of claims 7-11.

16. The method of claim 14 or 15, wherein the mutation is any mutation involving, surrounding, or affecting DMD exon 44.

17. The method of claim 16, wherein the mutation is a duplication of DMD exon 44, a deletion of exon 43 or 45, or a deletion of exons 45-56.

18. The method of any one of claims 14-17, wherein the administering results in increased expression of dystrophin protein in the subject.

19. The method of any one of claims 14-17, wherein the administering inhibits the progression of dystrophic pathology in the subject.

20. The method of any one of claims 14-17, wherein the administering improves muscle function in the subject.

21. The method of claim 20 wherein the improvement in muscle function is an improvement in muscle strength.

22. The method of claim 20 wherein the improvement in muscle function is an improvement in stability in standing and walking.

23. Use of at least one nucleic acid molecule of any one of claims 1-6 in treating, ameliorating, and/or preventing a muscular dystrophy in a subject with a mutation amenable to skipping exon 44 of the DMD gene (DMD exon 44).

24. Use of at least one rAAV of any one of claims 7-11 in treating, ameliorating, and/or preventing a muscular dystrophy in a subject with a mutation amenable to skipping exon 44 of the DMD gene (DMD exon 44).